Although the clinical application of ICIs is currently being expanded to a variety of malignancies, a combination of c-Met targeting therapies with ICIs should be considered in patients with MET-positive CTCs to improve the therapeutic efficacy of cancer immunotherapy. The gene discussed is MET; the disease is cancer.